目的 研究动物双歧杆菌TY-S01（TY-S01）对单纯性肥胖受试者体成分、炎症因子及肠道菌群的影响。方法 采用随机、双盲、安慰剂对照临床试验,招募30名单纯性肥胖成年人,随机分成两组,即试验组（TY-S01组）和安慰剂组,每组各15人,试验组每天饮用1包动物双歧杆菌TY-S01固体饮料（活菌含量约为每包5×1010CFU）,安慰剂组每天饮用1包安慰剂（麦芽糊精）,共干预12 w。干预前后各记录饮食信息、测量一次体成分,并采血液和粪便样本,检测血液中血脂、炎症因子、肝肾功能指标和粪便中菌群变化。结果 干预后,TY-S01组体脂率、内脏脂肪面积较干预前显著下降,且下降幅度显著大于安慰剂组;血清总胆固醇和低密度脂蛋白胆固醇的下降幅度显著大于安慰剂组;肿瘤坏死因子α含量较干预前显著降低。干预后,安慰剂组显著富集厌氧菌属、毛螺菌科属、粪球菌属等肥胖相关有害菌属,TY-S01组显著富集假单胞菌目、嗜肽菌属等有益菌属。相关性分析发现,厌氧菌属与血脂的增加呈显著正相关,毛螺菌科属与体脂、血脂、炎症因子的增加呈显著正相关,且干预后这两种菌属在TY-S01组的相对丰度显著低于安慰剂组。结论 本研究结果表明,动物双歧杆菌TY-S01能够降低单纯性肥胖受试者的体脂、血脂和炎症因子水平,其作用可能与该菌增加假单胞菌目和嗜肽菌属等有益菌属的相对丰度、降低厌氧菌属和毛螺菌科属的相对丰度有关。
Abstract
Objective To study the effects of Bifidobacterium simple obese adults animalis subsp. lactis TY-S01 (TY-S01) on body composition, inflammatory factors and gut microbiota in simple obese adults. Methods Thirty adults with simple obesity were recruited and randomly divided into two groups, including 15 in the test group (TY-S01 group), who consumed the TY-S01 solid drink (live bacteria content of 5×1010 CFU), and 15 in the control group, who consumed the placebo (maltodextrin) for 12 weeks. Dietary information was recorded and body composition was measured before and after intervention. Blood and stool samples were collected and tested for blood lipids, inflammatory factors, hepatic and renal function parameters and gut microbiota. Results After intervention, body fat percentage and visceral fat area decreased in the TY-S01 group. The decrease in body fat percentage, visceral fat area, serum total cholesterol and low-density lipoprotein cholesterol were significantly greater in the TY-S01 group than in the placebo group. Serum tumor necrosis factor α levels decreased significantly in the TY-S01 group. After intervention, the feces from the placebo group were significantly enriched in obesity-related harmful genera such as g__Anaerostipes, g__unclassified_f__Lachnospiraceae, and g__Coprococcus, while those from the TY-S01 group were significantly enriched in beneficial genera such as o__Pseudomonadales and g__Peptoniphilus. Correlation analysis revealed that g__Anaerostipes was significantly and positively correlated with increased body lipids, and g__unclassified_f__Lachnospiraceae was significantly and positively correlated with increased body fat, blood lipids, and inflammatory factors. Conclusion Our findings indicate that TY-S01 is effective in reducing body fat, blood lipids and inflammation levels in simple obese individuals possibly via the decreasing the abundances of g__Anaerostipes and g__unclassified_f__Lachnospiraceae and the increasing the abundances of o__Pseudomonadales and g__Peptoniphilus.
关键词
动物双歧杆菌TY-S01 /
肥胖 /
炎症 /
肠道菌群
Key words
Bifidobacterium animalis subsp. lactis TY-S01 /
obesity /
inflammation /
intestinal microbiome
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Pan XF, Wang LM, Pan A.Epidemiology and determinants of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9: 373–392.
[2] Gino S, Guido G.Obesity and hypertension[J]. Pharmacol Res, 2017, 122: 1–7.
[3] Ling C, Ronn T.Epigenetics in human obesity and type 2 diabetes[J]. Cell Metab, 2019, 29: 1028–1044.
[4] Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk,and treatment: a position paper of the Obesity Society and the American Society of Hypertension[J]. J Clin Hypertens, 2013, 15: 14–33.
[5] Gao Y, Wang Y, Zhou J, et al. Effectiveness of electroacupuncture for simple obesity: a systematic review and meta-analysis of randomized controlled trials[J]. Evid Based Complement Alternat Med, 2020, 2020: 2367610.
[6] Sikorska D, Grzymislawska M, Roszak M, et al. Simple obesity and renal function[J]. J Physiol Pharmacol, 2017, 68: 175–180
[7] 李怡璇,刘洋,闻德亮. 肥胖相关代谢性炎症研究进展[J]. 现代预防医学,2022, 49: 3246–3251.
[8] Mcnay DE, Speakman JR.High fat diet causes rebound weight gain[J]. Mol Metab,2012, 2: 103–108.
[9] Rohan K, Mohammad HM, Apoorva KC, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis[J]. JAMA, 2016, 315: 995.
[10] Kelly AS, Auerbach P, Barrientos-perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity[J]. N Engl J Med, 2020, 382: 2117–2128.
[11] Sutcliffe RP, Forshaw MJ, Tandon R, et al. Anastomotic strictures and delayed gastric emptying after esophagectomy: incidence, risk factors and management[J]. Dis Esophagus, 2008, 21: 712–717.
[12] Hill C, Guarner F, Reid G, et al. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic[J]. Nat Rev Gastroenterol Hepatol,2014, 11: 506–514.
[13] Zhong H, Abdullah, Deng LL, et al. Probiotic-fermented blueberry juice prevents obesity and hyperglycemia in high fat diet-fed mice in association with modulating the gut microbiota[J]. Food Funct, 2020, 11: 9192–9207.
[14] Cai HY, Wen ZG, Li XM, et al. Lactobacillus plantarum FRT10 alleviated high-fat diet-induced obesity in mice through regulating the PPARα signal pathway and gut microbiota[J]. Appl Microbiol Biotechnol, 2020, 104: 5959–5972.
[15] Kong C, Gao R, Yan X, et al. Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet[J]. Nutrition, 2018, 60: 175–184.
[16] Kadooka Y, Sato M, Imaizumi K, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial[J]. Eur J Clin Nutr, 2010, 64: 636–643.
[17] Kim J, Yun JM, Kim MK, et al. Lactobacillus gasseri BNR17 supplementation reduces the visceral fat accumulation and waist circumference in obese adults: a randomized, double-blind, placebo-controlled trial[J]. J Med Food, 2018, 21: 454–461.
[18] Zarrati M, Shidfar F, Nourijelyani K, et al. Lactoba-cillus acidophilus La5, Bifidobacterium BB12, and Lactobacillus casei DN001 modulate gene expression of subset specific transcription factors and cytokines in peripheral blood mononuclear cells of obese and overweight people[J]. Biofactors, 2013, 39: 633–643.
[19] Michael DR, Jack AA, Masetti G, et al. A randomised controlled study shows supplementation of overweight and obese adults with Lactobacilli and Bifidobacteria reduces body weight and improves well-being[J]. Sci Rep,2020, 10: 4183.
[20] Tang T, Wang J, Jiang YY, et al. Bifidobacterium lactis TY-S01 prevents loperamide-induced constipation by modulating gut microbiota and its metabolites in mice[J]. Front Nutr, 2022, 9: 890314.
[21] Shu X, Wang J, Zhao L, et al. Bifidobacterium lactis TY-S01 protects against alcoholic liver injury in mice by regulating intestinal barrier function and gut microbiota[J]. Heliyon, 2023, 9: e17878.
[22] 危北海,贾葆鹏. 单纯性肥胖病的诊断及疗效评定标准[J]. 中国中西医结合杂志, 1998: 317–319.
[23] Yin Y, Zhao Q, Li S, et al. Efficacy of acupuncture and moxibustion therapy for simple obesity in adults: A meta-analysis of randomized controlled trials[J]. Medicine, 2022, 101: e31148.
[24] Kim M, Kang M, Yoo HJ, et al. Effects of weight loss using supplementation with Lactobacillus strains on body fat and medium-chain acylcarnitines in overweight individuals[J]. Food Funct, 2017, 8: 250–261.
[25] Johnstone AM, Kelly J, Ryan S, et al. Nondigestible carbohydrates affect metabolic health and gut microbiota in overweight adults after weight loss[J]. J Nutr, 2020, 150: 1859–1870.
[26] Ward CS, Yung C, Davis KM, et al. Annual community patterns are driven by seasonal switching between closely related marine bacteria[J]. Isme J, 2017, 11: 1412–1422.
[27] Fang H, Berg E, Cheng X, et al. How to best assess abdominal obesity[J]. Curr Opin Clin Nutr Metab Care, 2018, 21: 360–365.
[28] Barazzoni R, Bischoff S, Boirie Y, et al. Sarcopenic obesity: time to meet the challenge[J]. Obes Facts, 2018, 11: 294–305.
[29] Kobyliak N, Abenavoli L, Falalyeyeva T, et al. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study[J]. Minerva Med, 2018, 109: 418–428.
[30] Duncan MS, Vasan RS, Xanthakis V.Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality: observations from the Framingham study over 35 years[J]. J Am Heart Assoc, 2019, 8: e11433.
[31] 诸骏仁,高润霖,赵水平,等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31: 937–953.
[32] Calle MC, Fernandez ML.Inflammation and type 2 diabetes[J]. Diabetes Metab, 2012, 38: 183–191.
[33] Zhao X, Chen Y, Li L, et al. Effect of DLT-SML on chronic stable angina through ameliorating inflammation, correcting dyslipidemia, and regulating gut microbiota[J]. J Cardiovasc Pharmacol, 2021, 77: 458–469.
[34] Zhou L, Ni ZX, Yu J, et al. Correlation between fecal metabolomics and gut microbiota in obesity and polycystic ovary syndrome[J]. Front Endocrinol, 2020, 11: 628.
[35] Xia F, Xiang SJ, Chen ZJ, et al. The probiotic effects of AB23A on high-fat-diet-induced non-alcoholic fatty liver disease in mice may be associated with suppressing the serum levels of lipopolysaccharides and branched-chain amino acids[J]. Arch Biochem Biophys, 2021, 714: 109080.
[36] Qiu WH, Liu T, Liu XJ, et al. Enrofloxacin induces intestinal microbiota-mediated immunosuppression in zebrafish[J]. Environ Sci Technol, 2022, 56: 8428–8437.
[37] Yu C, Guo C, Geng X, et al. Effects of fruits and vegetables on gut microbiota in a mouse model of metabolic syndrome induced by high-fat diet[J]. Food Sci Nutr, 2023, 2: 794–805.
[38] 马良坤,薛勇,何婷超,等.孕晚期妇女的社会经济学因素、营养素摄入、肠道菌群和孕期增重的关系[J]. 中国医学科学院学报, 2018, 40: 630–636.
[39] Zeng Q, Li DF, He Y, et al. Discrepant gut microbiota markers for the classification of obesity-related metabolic abnormalities[J]. Sci Rep, 2019, 9: 13424
[40] Wang CS, Li WB, Wang HY, et al. VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice [J]. World J Gastroenterol, 2018, 24: 4254－4262.
基金
中央高校基本科研业务费专项资金(No.2023TC015; No.2023TC016)
